anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The perception that the nucleoli are merely the organelles where ribosome biogenesis occurs is challenged. Only around 30 % of nucleolar proteins are solely involved in producing ribosomes. Instead, the nucleolus plays a critical role in controlling protein trafficking during stress and, according to its dynamic nature, undergoes continuous protein exchange with nucleoplasm under various cellular stressors. Hence, the concept of nucleolar stress has evolved as cellular insults that disrupt the structure and function of the nucleolus. Considering the emerging role of this organelle in DNA repair and the fact that rDNAs are the most fragile genomic loci, therapies targeting the nucleoli are increasingly being developed. Besides, drugs that target ribosome synthesis and induce nucleolar stress can be used in cancer therapy. In contrast, agents that regulate nucleolar activity may be a potential treatment for neurodegeneration caused by abnormal protein accumulation in the nucleolus. Here, I explore the roles of nucleoli beyond their ribosomal functions, highlighting the factors triggering nucleolar stress and their impact on genomic stability.
Systemic sclerosis (SSc) is a connective tissue disease for which skin tightness is the hallmark. The disease is classified into 2 major subsets: limited cutaneous systemic sclerosis (lcSSc) and diffuse cutaneous systemic sclerosis (dcSSc) depending on the extent of skin tightness. Not only the skin tightness but also the internal organs such as the musculoskeletal, kidneys, lungs, heart, and intestines can be involved and associated with a poor outcome. Malnutrition and/or weight loss is a complications in SSc. The complication is possibly related to gastrointestinal involvement, inflammation, immunosuppressant agents, or mood disturbance which can affect the food appetite or eating behavior. As well as sleep quality, sleep disturbance has been reported in SSc patients and the associated factor of sleep disturbance in those patients was gastrointestinal involvement, particularly gastroesophageal reflux disease, the severity of pain, and depressed mood. The cannabinoid is an agent which affects appetite, pain, and sleep quality as mentioned above, hence it would improve the appetite, get a high sleep quality and reduce pain associated with musculoskeletal involvement in SSc patients.

Although cannabinoid has benefit in many aspects, they also resulted in serious adverse events after cannabinoid inhalation, including ischemic stroke related to vasospasm of the cerebral vessel, high cardiac output, cardiac arrhythmias, blood pressure fluctuation, and respiratory tract infection. Acute toxicity has been reported and depended on unit dose, tolerance, and route of cannabinoid use. Cannabis also influenced brain function including memory, and cognitive function, and expanded the risk for psychosis in those who had prolonged use. The symptoms of central nervous system (CNS) toxicity include euphoria, panic, agitation, mood alterations, alteration of perception, loss of social inhibition, muscle incoordination, myoclonic jerking, ataxia, slurred speech, and risk of the suicidal idea. In addition, prolonged high doses of cannabis use can lead to the development of cannabinoid hyperemesis syndrome caused by cyclic hyperemesis, finally resulting in electrolyte disturbances and impaired kidney function.

Because the evidence of the effect of cannabinoids in humans with SSc is limited. We, therefore, would like to investigate the efficacy of cannabinoids on the appetite, sleep efficiency, quality of life, pain, and key cytokine level in SSc compared with placebo in SScpatientst and the adverse events associated with cannabinoids in those patients.
Patients receive cixutumumab IV over 1 hour on days 1, 8, 15, and 22 and oral sorafenib tosylate twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Despite having high analytical sensitivities and specificities, qualitative SARS-CoV-2 nucleic acid amplification tests (NAATs) cannot distinguish infectious from non-infectious virus in clinical samples. In this study, we determined the highest cycle threshold (Ct) value of the SARS-CoV-2 targets in the Xpert Xpress SARS-CoV-2/Flu/RSV (Xpert 4plex) test that corresponded to the presence of detectable infectious SARS-CoV-2 in anterior nasal swab samples. A total of 111 individuals with nasopharyngeal swab specimens that were initially tested by the Xpert Xpress SARS-CoV-2 test were enrolled. A healthcare worker subsequently collected anterior nasal swabs from all SARS-CoV-2-positive individuals, and those specimens were tested by the Xpert 4plex test, viral culture, and laboratory-developed assays for SARS-CoV-2 replication intermediates. SARS-CoV-2 Ct values from the Xpert 4plex test were correlated with data from culture and replication intermediate testing to determine the Xpert 4plex assay Ct value that corresponded to the presence of infectious virus. Ninety-eight of the 111 (88.3%) individuals initially tested positive by the Xpert Xpress SARS-CoV-2 test. An anterior nasal swab specimen collected from positive individuals a median of 2 days later (range, 0-9 days) tested positive for SARS-CoV-2 by the Xpert 4plex test in 39.8% (39/98) of cases. Of these samples, 13 (33.3%) were considered to contain infectious virus based on the presence of cultivable virus and replication intermediates, and the highest Ct value observed for the Xpert 4plex test in these instances was 26.3. Specimens that yielded Ct values of ≤26.3 when tested by the Xpert 4plex test had a likelihood of containing infectious SARS-CoV-2; however, no infectious virus was detected in specimens with higher Ct values.IMPORTANCEUnderstanding the correlation between real-time PCR test results and the presence of infectious SARS-CoV-2 may be useful for informing patient management and workforce return-to-work or -duty. Further studies in different patient populations are needed to correlate Ct values or other biomarkers of viral replication along with the presence of infectious virus in clinical samples.
PURPOSE: To obtain the subject therapeutic agent comprising a dihydro- prostaglandin F2 β derivative or its salt as an active ingredient, having excellent vasodilating action on constriction of blood vessel of retina, effective for retinal circulatory disorder. CONSTITUTION: This therapeutic agent for retinopathy comprises a 13,14-dihydro- prostaglandin F2 β derivative of the formula (R is H, a lower alkyl, a cycloalkyl, phenyl or a phenyl lower alkyl) or its salt as an active ingredient. A compound wherein R is H or isopropyl is preferable among the compounds of the formula. The objective therapeutic agent, for example, can be prepared as an eye drop by using an isotonizing agent such as concentrated glycerol, a buffering agent such as sodium phosphate, etc., an antiseptic such as paraben, etc. The preparation is preferably carried out at pH4 to pH8. A daily dose is preferably 0.1-50mg in the case of an injection and administered once or several times dividedly. In the case of an eye drop, 0.02-0.1% solution is dropped once to several times daily.
The present invention relates to a novel RNA picornavirus that is called Seneca Valley virus (“SVV”). The invention provides isolated SVV nucleic acids and proteins encoded by these nucleic acids. Further, the invention provides antibodies that are raised against the SVV proteins. Because SVV has the ability to selectively kill some types of tumors, the invention provides methods of using SVV and SVV polypeptides to treat cancer. Because SVV specifically targets certain tumors, the invention provides methods of using SVV nucleic acids and proteins to detect cancer. Additionally, due to the information provided by the tumor-specific mechanisms of SVV, the invention provides methods of making new oncolytic virus derivatives and of altering viruses to have tumor-specific tropisms.
<P>PROBLEM TO BE SOLVED: To provide a laminate composed of a polyvinyl alcohol which can be simply manufactured.  <P>SOLUTION: This laminate is obtained by superposing a polyvinyl alcohol composition layer on a support, and the composition layer is formed by applying and drying an aqueous polyvinyl alcohol solution containing inorganic salt. The inorganic salt is water-soluble and can contain water of crystallization. This laminate is composed of not less than two laminated polyvinyl alcohol composition layers, each varying in the inorganic salt concentration. This laminate also can comprise a laminated hydrogel layer.  <P>COPYRIGHT: (C)2009,JPO&INPIT
<P>PROBLEM TO BE SOLVED: To provide a physiologically permissible oral dosage form of a definite multi-layered type, corresponding to various pharmaceutically active compounds.  <P>SOLUTION: The dosage form contains a definite central core, definite middle layer and definite outside outer shell layer, and at least one of them contains at least 1 kind of pharmaceutically active substance. By changing the diameter of the core, different middle layer volumes are obtained in a definite and fixed range of the outside outer shell layer dimension. Thereby, without requiring a work for re-formulation, a capacity of obtaining different dosage potencies corresponding to the one kind of composition is provided. An oral dosage form is produced by a continuous treatment of a single process of coating the core with the middle layer and outside outer shell layer.  <P>COPYRIGHT: (C)2004,JPO
A beta-carboline alkaloid-based eudistomin derivative having a novel antibacterial is provided to have excellent antibacterial activation against a gram-positive bacteria without cytotoxicity. A beta-carboline alkaloid-based eudistomin derivatives of the chemical formula 1 is isolated from a marine Eudistoma sp. In the chemical formula 1, R1-R4 are separately a hydrogen, Br, except the R1-R4 are Br. An antibacterial pharmaceutical composition comprises beta-carboline alkaloid-based eudistomin derivatives of the chemical formula 1 as an effective ingredient. A bacteria is a gram-positive pathogenic bacteria including a Staphylococcus or Bacillus. The Staphylococcus is Staphylococcus epidermidis and Bacillus is Bacillus subtilis.
The invention comprises compounds of the formula <FORM:1016372/C2/1> wherein the dotted line in ring A denotes the optional presence of double bonds, R1 represents a hydrogen atom or a methyl group, R2 represents two hydrogen atoms when a D 4 double bond is absent, or a hydrogen or chlorine atom or a hydroxyl group when a D 4 double bond is present, R3 represents a hydrogen atom or an alkyl group preferably having less than six carbon atoms, R4 represents two hydrogen atoms or one hydrogen atom with an a -methyl group, and X represents a chlorine atom or the group -OR in which R represents an alkyl, alkenyl, cycloalkyl, aryl, halo-substituted aryl, aralkyl, alkaryl, alkoxyaryl, aryloxy alkyl or heterocyclic radical.  The compounds may be prepared by direct acylation of a steroid compound having a hydroxy group in the 17b  position with chlorosulphonylacetyl chloride in an inert solvent to give the sulphonyl chloride. The sulphonate esters may be prepared by reaction of the sulphonyl chloride so produced with an alcohol or directly by addition of an alcohol during the acylation.  The sulphoacetates may be prepared from 3,17-androstenediones by protecting the D 4-3-keto position, reducing the 17-keto group and reacting with chlorosulphonyl acetyl chloride.  Esters of testosterone-17-sulphoacetate may be prepared by treating testosterone with a Grignard reagent and reacting the resulting 17-halomagnesium compound with chlorosulphonylacetyl chloride and an alcohol.  Therapeutic compositions with anabolic and androgenic properties, in the form of oil solutions or aqueous suspensions for parenteral administration, contain esters of androstaneand estrane-17-sulphoacetates of the above general formula.
BACKGROUND: The Society for Cardiovascular Angiography and Interventions proposed a staging system (A-E) to predict prognosis in cardiogenic shock. Herein, we report clinical outcomes of the RECOVER III study for the first time, according to Society for Cardiovascular Angiography and Interventions shock classification.
METHODS AND RESULTS: The RECOVER III study is an observational, prospective, multicenter, single-arm, postapproval study of patients with acute myocardial infarction with cardiogenic shock undergoing percutaneous coronary intervention with Impella support. Patients enrolled in the RECOVER III study were assigned a baseline Society for Cardiovascular Angiography and Interventions shock stage. Staging was then repeated within 24 hours after initiation of Impella. Kaplan-Meier survival curve analyses were conducted to assess survival across Society for Cardiovascular Angiography and Interventions shock stages at both time points. At baseline assessment, 16.5%, 11.4%, and 72.2% were classified as stage C, D, and E, respectively. At ≤24-hour assessment, 26.4%, 33.2%, and 40.0% were classified as stage C, D, and E, respectively. Thirty-day survival among patients with stage C, D, and E shock at baseline was 59.7%, 56.5%, and 42.9%, respectively (P=0.003). Survival among patients with stage C, D, and E shock at ≤24 hours was 65.7%, 52.1%, and 29.5%, respectively (P<0.001). After multivariable analysis of impact of shock stage classifications at baseline and ≤24 hours, only stage E classification at ≤24 hours was a significant predictor of mortality (odds ratio, 4.8; P<0.001).
CONCLUSIONS: In a real-world cohort of patients with acute myocardial infarction with cardiogenic shock undergoing percutaneous coronary intervention with Impella support, only stage E classification at ≤24 hours was significantly predictive of mortality, suggesting that response to therapy may be more important than clinical severity of shock at presentation.
The invention discloses a biomarker for predicting NSCLC radiotherapy resistance and application thereof, and relates to the technical field of biological medicines. The biomarker is Fibulin-5. The invention screens Fibulin to be highly expressed in the NSCLC resisting radiotherapy by bioinformatics technology, and proves that Fibulin-5 expression is related to poor prognosis of NSCLC patients by a tissue immunohistochemical method, so that the radiotherapy curative effect can be predicted. In vitro and in vivo experiments prove that inhibiting Fibulin-5 expression can slow down tumor growth and increase radiation sensitivity. Also demonstrated is Fibulin that enhances radiation resistance of NSCLC by modulating the Src-STAT3-ACSL4 axis to inhibit iron death. The invention has important clinical application value for the radiotherapy resistance of NSCLC and the radiotherapy curative effect prediction, prognosis evaluation and improvement of the radiotherapy resistance of NSCLC.
The investigators apply the Laser Acupuncture pen (without pressing the laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
Intercellular mitochondrial transfer (MT) is a newly discovered form of cell-to-cell signalling involving the active incorporation of healthy mitochondria into stressed/injured recipient cells, contributing to the restoration of bioenergetic profile and cell viability, reduction of inflammatory processes and normalisation of calcium dynamics. Recent evidence has shown that MT can occur through multiple cellular structures and mechanisms: tunneling nanotubes (TNTs), via gap junctions (GJs), mediated by extracellular vesicles (EVs) and other mechanisms (cell fusion, mitochondrial extrusion and migrasome-mediated mitocytosis) and in different contexts, such as under physiological (tissue homeostasis and stemness maintenance) and pathological conditions (hypoxia, inflammation and cancer). As Mesenchimal Stromal/ Stem Cells (MSC)-mediated MT has emerged as a critical regulatory and restorative mechanism for cell and tissue regeneration and damage repair in recent years, its potential in stem cell therapy has received increasing attention. In particular, the potential therapeutic role of MSCs has been reported in several articles, suggesting that MSCs can enhance tissue repair after injury via MT and membrane vesicle release. For these reasons, in this review, we will discuss the different mechanisms of MSCs-mediated MT and therapeutic effects on different diseases such as neuronal, ischaemic, vascular and pulmonary diseases. Therefore, understanding the molecular and cellular mechanisms of MT and demonstrating its efficacy could be an important milestone that lays the foundation for future clinical trials.
Obesity is associated with neurocognitive dysfunction, including memory deficits. This is particularly worrisome when obesity occurs during adolescence, a maturational period for brain structures critical for cognition. In rodent models, we recently reported that memory impairments induced by obesogenic high-fat diet (HFD) intake during the periadolescent period can be reversed by chemogenetic manipulation of the ventral hippocampus (vHPC). Here, we used an intersectional viral approach in HFD-fed male mice to chemogenetically inactivate specific vHPC efferent pathways to nucleus accumbens (NAc) or medial prefrontal cortex (mPFC) during memory tasks. We first demonstrated that HFD enhanced activation of both pathways after training and that our chemogenetic approach was effective in normalizing this activation. Inactivation of the vHPC-NAc pathway rescued HFD-induced deficits in recognition but not location memory. Conversely, inactivation of the vHPC-mPFC pathway restored location but not recognition memory impairments produced by HFD. Either pathway manipulation did not affect exploration or anxiety-like behaviour. These findings suggest that HFD intake throughout adolescence impairs different types of memory through overactivation of specific hippocampal efferent pathways and that targeting these overactive pathways has therapeutic potential.
PURPOSE OF REVIEW: This systematic review investigates the recent literature and aims to determine the approach, efficacy, and timing of facial nerve decompression with or without grafting in temporal bone fractures with facial palsy.
RECENT FINDINGS: The surgical management of facial palsy is reserved for a small population of cases in which electrophysiologic tests indicate a poor likelihood of spontaneous recovery. The transmastoid (TM), middle cranial fossa (MCF), and translabyrinthine (TL) approaches to the facial nerve provide access to the entire intracranial and intratemporal segments of the facial nerve. In temporal bone (TB) related facial palsy, the peri-geniculate and labyrinthine portions of the facial nerve are most commonly affected by either direct trauma and/or subsequent edema. When hearing is still serviceable, the combined TM/MCF approach provides the best access to these regions. In the presence of severe sensorineural hearing loss (SNHL), the TL approach is the most appropriate for total facial nerve exploration (this can be done in conjunction with simultaneous cochlear implantation if the cochlear nerve has not been avulsed). Grade I to III House-Brackmann (HB) results can be anticipated in timely decompression of facial nerve injury caused by edema or intraneuronal hemorrhage. Grade III outcomes, with slight weakness and synkinesis, is the outcome to be expected from the use of interpositional grafts or primary neurorrhaphy. In addition to good eye care and the use of systemic steroids (if not contraindicated in the acute trauma setting), surgical decompression with or without grafting/neurorrhaphy may be offered to patients with appropriate electrophysiologic testing, physical examination findings, and radiologic localization of injury.
SUMMARY: Surgery of the facial nerve remains an option for select patients. Here, we discuss the indications and results of treatment as well as the best surgical approach to facial nerve determined based on patient's hearing status and radiologic data. Controversy remains about whether timing of surgery (e.g., immediate vs. delayed intervention) impacts outcomes. However, no one with facial palsy due to a temporal bone fracture should be left with a complete facial paralysis.
<P>PROBLEM TO BE SOLVED: To provide a system, which can retrieve and investigate medical information of patients in the state of anonymity so that the number of patient candidates, who are to be subjects for clinical trials, is increased and the success rate of subject solicitation is improved.  <P>SOLUTION: Medical information of a patient is divided into a first information part, which is included with personal specified information on the patient and specified information on a doctor in charge, and a second information part, which is included with clinical information of the patient, artificial statistical information and information to specify the doctor for the patient, and then independently stored. Each patient is assigned with a unique patient identification code, and the code is inputted into both of the information parts. A third-person retriever investigates the second information stored part to acquire information necessary for a clinical trial plan, and obtains the number of candidates without specifying patients. A doctor for the patients who are candidates has an access right to retrieve the first information part based on patient identification codes. The doctor, who is requested from the third-person retriever, can solicit participants for the clinical trial.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Peer mentors who have experience of depression are trained and supervised to deliver depression care. Peers will meet with depressed older adults for 8 weekly meeting lasting approximately 45 minutes. Peer mentors will provide social support defined as emotional, informational and appraisal support that includes coping strategies. Peers will be supervised by a mental health professional.
To address the limitations of conventional sentinel lymph node biopsy (SLNB), a novel hybrid tracer (indocyanine green [ICG]-99mTc-nanocolloid) has been developed. This meta-analysis aimed to compare the differences between the novel hybrid tracer and conventional methods using ICG or radioisotope (RI) for SLNB in head and neck malignancies. This study was registered in the International Prospective Register of Systematic Reviews (CRD42023409127). PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched. This study included raw data on the number of sentinel lymph nodes (SLNs) identified using different modalities during surgery for head and neck malignancies. The identification rate of SLNs was the main outcome of interest. Prognostic data and complication rate cannot be deduced from this article. The heterogeneity test (I2) determined the use of a fixed- or random-effects model for the pooled risk ratio (RR). Overall, 1275 studies were screened, of which 11 met the inclusion criteria for the meta-analysis. In SLN identification of head and neck malignancies, ICG-99mTc-nanocolloid was superior to ICG or RI. In the subgroup analyses, the detection rates of ICG and RI tracers in SLNB were comparable, regardless of the device, tumor type, or tumor stage. In conclusion, in SLN identification of head and neck malignancies, the use of ICG-99mTc-nanocolloid is superior to the single technique of ICG or RI. This study suggests that Hospitals using ICG or RI may find it beneficial to change their practice to ICG-99mTc-nanocolloid, especially in the head and neck area, owing to its superior effectiveness.
Patients who have had surgical management of ankle fracture will be given a standing regimen (scheduled doses) of 500 mg naproxen twice a day and will have received one intraoperative dose of ketorolac. Patients will have a prescription for opioids for breakthrough pain.